» Articles » PMID: 29719390

Smart Polymeric Nanoparticles with PH-responsive and PEG-detachable Properties for Co-delivering Paclitaxel and Survivin SiRNA to Enhance Antitumor Outcomes

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2018 May 3
PMID 29719390
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The co-delivery of chemotherapeutic agents and small interfering RNA (siRNA) within one cargo can enhance the anticancer outcomes through its synergistic therapeutic effects.

Materials And Methods: We prepared smart polymeric nanoparticles (NPs) with pH-responsive and poly(ethylene glycol) (PEG)-detachable properties to systemically co-deliver paclitaxel (PTX) and siRNA against survivin gene for lung cancer therapy. The cationic polyethyleneimine-block-polylactic acid (PEI-PLA) was first synthesized and characterized, with good biocompatibility. PTX was encapsulated into the hydrophobic core of the PEI-PLA polymers by dialysis, and then the survivin siRNA was loaded onto the PTX-loaded NPs (PEI-PLA/PTX) through electrostatic interaction between siRNA and PEI block. Finally, the negatively charged poly(ethylene glycol)-block-poly(L-aspartic acid sodium salt) (PEG-PAsp) was coated onto the surface of NPs by electrostatic interaction to form final smart polymeric NPs with mean particle size of 82.4 nm and zeta potential of 4.1 mV. After uptake of NPs by tumor cells, the PEG-PAsp segments became electrically neutral owing to the lower endosome pH and consequently detached from the smart NPs. This process allowed endosomal escape of the NPs through the proton-sponge effect of the exposed PEI moiety.

Results: The resulting NPs achieved drug loading of 6.04 wt% and exhibited good dispersibility within 24 h in 10% fetal bovine serum (FBS). At pH 5.5, the NPs presented better drug release and cellular uptake than at pH 7.4. The NPs with survivin siRNA effectively knocked down the expression of survivin mRNA and protein owing to enhanced cell uptake of NPs. Cell counting kit-8 (CCK-8) assay showed that the NPs presented low systemic toxicity and improved antiproliferation effect of PTX on A549 cells. Moreover, in vivo studies demonstrated that accumulated NPs in the tumor site were capable of inhibiting the tumor growth and extending the survival rate of the mice by silencing the survivin gene and delivering PTX into tumor cells simultaneously.

Conclusion: These results indicate that the prepared nano-vectors could be a promising co-delivery system for novel chemo/gene combination therapy.

Citing Articles

Polymeric nanocarriers for therapeutic gene delivery.

Zhang J, Yang X, Chang Z, Zhu W, Ma Y, He H Asian J Pharm Sci. 2025; 20(1):101015.

PMID: 39931356 PMC: 11808530. DOI: 10.1016/j.ajps.2025.101015.


Targeted Nanotherapy by Vinblastine-Loaded Chitosan-Coated PLA Nanoparticles to Improve the Chemotherapy via Reactive Oxygen Species to Hamper Hepatocellular Carcinoma.

Singh A, Bora S, Kumar P, Kukreti R, Kaushik M ACS Omega. 2025; 10(1):170-180.

PMID: 39829490 PMC: 11739963. DOI: 10.1021/acsomega.4c02983.


Preparation and effects of functionalized liposomes targeting breast cancer tumors using chemotherapy, phototherapy, and immunotherapy.

Zeng B, Pian L, Liu Y, Wang S, Wang N, Liu C J Nanobiotechnology. 2024; 22(1):558.

PMID: 39267061 PMC: 11391708. DOI: 10.1186/s12951-024-02838-1.


Current advance of nanotechnology in diagnosis and treatment for malignant tumors.

Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y Signal Transduct Target Ther. 2024; 9(1):200.

PMID: 39128942 PMC: 11323968. DOI: 10.1038/s41392-024-01889-y.


Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell.

Firouzi Amandi A, Bahmanyar Z, Dadashpour M, Lak M, Natami M, Dogus Y Cancer Cell Int. 2024; 24(1):46.

PMID: 38287318 PMC: 10826113. DOI: 10.1186/s12935-024-03219-2.


References
1.
Kang L, Fan B, Sun P, Huang W, Jin M, Wang Q . An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome. Acta Biomater. 2016; 44:341-54. DOI: 10.1016/j.actbio.2016.08.029. View

2.
Han K, Chen S, Chen W, Lei Q, Liu Y, Zhuo R . Synergistic gene and drug tumor therapy using a chimeric peptide. Biomaterials. 2013; 34(19):4680-9. DOI: 10.1016/j.biomaterials.2013.03.010. View

3.
Coumar M, Tsai F, Kanwar J, Sarvagalla S, Cheung C . Treat cancers by targeting survivin: just a dream or future reality?. Cancer Treat Rev. 2013; 39(7):802-11. DOI: 10.1016/j.ctrv.2013.02.002. View

4.
Ishida O, Maruyama K, Sasaki K, IWATSURU M . Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm. 1999; 190(1):49-56. DOI: 10.1016/s0378-5173(99)00256-2. View

5.
Zheng C, Zheng M, Gong P, Deng J, Yi H, Zhang P . Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials. 2013; 34(13):3431-8. DOI: 10.1016/j.biomaterials.2013.01.053. View